Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Comparison of SureSelect and Nextera Exome Capture Performance in Single-Cell Sequencing.

Huss WJ, Hu Q, Glenn ST, Gangavarapu KJ, Wang J, Luce JD, Quinn PK, Brese EA, Zhan F, Conroy JM, Paragh G, Foster BA, Morrison CD, Liu S, Wei L.

Hum Hered. 2018;83(3):153-162. doi: 10.1159/000490506. Epub 2019 Jan 22.

2.

The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.

Sabnis NG, Miller A, Titus MA, Huss WJ.

Mol Cancer Res. 2017 Feb;15(2):128-140. doi: 10.1158/1541-7786.MCR-16-0270-T. Epub 2016 Nov 17.

3.
4.

Impact of devascularization and tissue procurement on cell number and RNA integrity in prostatectomy tissue.

Payne Ondracek R, Cheng J, Gangavarapu KJ, Azabdaftari G, Woltz J, Brese E, Omilian A, Bshara W, Huss WJ, Mohler JL, Marshall JR.

Prostate. 2015 Dec;75(16):1910-5. doi: 10.1002/pros.23087. Epub 2015 Sep 9.

5.

Multi-Drug Resistance ABC Transporter Inhibition Enhances Murine Ventral Prostate Stem/Progenitor Cell Differentiation.

Samant MD, Jackson CM, Felix CL, Jones AJ, Goodrich DW, Foster BA, Huss WJ.

Stem Cells Dev. 2015 May 15;24(10):1236-51. doi: 10.1089/scd.2014.0293. Epub 2015 Feb 25.

6.

Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.

Liao J, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, Qian Z, Wang X, Huss WJ, Lele SB, Morrison CD, Odunsi K.

PLoS One. 2014 Jan 7;9(1):e84941. doi: 10.1371/journal.pone.0084941. eCollection 2014.

7.
8.

Human prostate side population cells demonstrate stem cell properties in recombination with urogenital sinus mesenchyme.

Foster BA, Gangavarapu KJ, Mathew G, Azabdaftari G, Morrison CD, Miller A, Huss WJ.

PLoS One. 2013;8(1):e55062. doi: 10.1371/journal.pone.0055062. Epub 2013 Jan 31.

9.

Isolation and applications of prostate side population cells based on dye cycle violet efflux.

Gangavarpu KJ, Huss WJ.

Curr Protoc Toxicol. 2011 Feb;Chapter 22:Unit 22.2. doi: 10.1002/0471140856.tx2202s47.

10.

ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate.

Mathew G, Timm EA Jr, Sotomayor P, Godoy A, Montecinos VP, Smith GJ, Huss WJ.

Cell Cycle. 2009 Apr 1;8(7):1053-61. Epub 2009 Apr 30.

11.

Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.

Sotomayor P, Godoy A, Smith GJ, Huss WJ.

Prostate. 2009 Mar 1;69(4):401-10. doi: 10.1002/pros.20895.

12.

Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell.

Godoy A, Watts A, Sotomayor P, Montecinos VP, Huss WJ, Onate SA, Smith GJ.

Endocrinology. 2008 Jun;149(6):2959-69. doi: 10.1210/en.2007-1078. Epub 2008 Feb 21.

13.

Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.

Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA, Greenberg NM, Smith GJ.

Neoplasia. 2007 Nov;9(11):938-50.

14.

Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.

Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ.

Cancer Res. 2005 Aug 1;65(15):6640-50.

15.

Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.

Wu GJ, Fu P, Chiang CF, Huss WJ, Greenberg NM, Wu MW.

J Urol. 2005 May;173(5):1778-83.

PMID:
15821586
16.

Retinoic acid slows progression and promotes apoptosis of spontaneous prostate cancer.

Huss WJ, Lai L, Barrios RJ, Hirschi KK, Greenberg NM.

Prostate. 2004 Oct 1;61(2):142-52.

PMID:
15305337
18.

Evidence of pluripotent human prostate stem cells in a human prostate primary xenograft model.

Huss WJ, Gray DR, Werdin ES, Funkhouser WK Jr, Smith GJ.

Prostate. 2004 Jul 1;60(2):77-90.

PMID:
15162374
19.

Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis.

Gray DR, Huss WJ, Yau JM, Durham LE, Werdin ES, Funkhouser WK Jr, Smith GJ.

Cancer Res. 2004 Mar 1;64(5):1712-21.

20.

Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype.

Evangelou AI, Winter SF, Huss WJ, Bok RA, Greenberg NM.

J Cell Biochem. 2004 Mar 1;91(4):671-83. Review.

PMID:
14991759
21.
22.

SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.

Huss WJ, Barrios RJ, Greenberg NM.

Mol Cancer Ther. 2003 Jul;2(7):611-6.

23.

Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.

Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM.

Prostate. 2003 May 15;55(3):219-37.

PMID:
12692788
24.
25.

Autochthonous mouse models for prostate cancer: past, present and future.

Huss WJ, Maddison LA, Greenberg NM.

Semin Cancer Biol. 2001 Jun;11(3):245-60. Review.

PMID:
11407949
26.

Angiogenesis and prostate cancer: identification of a molecular progression switch.

Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM.

Cancer Res. 2001 Mar 15;61(6):2736-43.

Supplemental Content

Support Center